Table 2.
Characteristics of the 1409 assessable testicular cancer survivors according to treatment group*
| Characteristic | Surveillance (n = 119) | RPLND (n = 153) | Radiotherapy (n = 609) | Chemotherapy |
Total (n = 1409) | P§ | ||
| 1–4 cycles† (n = 425) | ≥5 cycles† (n = 46) | Dose intensive†‡ (n = 57) | ||||||
| Age, median (range), y | ||||||||
| At treatment | 30 (17–64) | 28 (16–58) | 35 (18–64) | 29 (15–64) | 27 (16–62) | 24 (15–57) | 32 (15–64) | <.001║ |
| At survey | 39 (24–73) | 42 (28–75) | 47 (25–75) | 42 (23–73) | 36 (23–72) | 35 (24–75) | 43 (23–75) | <.001║ |
| Histology, No. (%) | <.001 | |||||||
| Seminoma | 8 (7) | 3 (2) | 607 (99) | 79 (19) | 7 (15) | 4 (7) | 708 (50) | |
| Nonseminoma | 111 (93) | 150 (98) | 2 (1) | 346 (81) | 39 (85) | 53 (93) | 701 (50) | |
| Initial tumor stage¶, No. (%) | <.001 | |||||||
| I | 119 (100) | 147 (96) | 578 (95) | 143 (34) | 5 (11) | 9 (16) | 1001 (71) | |
| IM | — | — | — | 6 (1) | 0 | 1 (2) | 7 (1) | |
| II | — | 6 (4) | 31 (5) | 202 (48) | 18 (39) | 11 (19) | 268 (19) | |
| III | — | — | — | 18 (4) | 6 (13) | 6 (10) | 30 (2) | |
| IV | — | — | — | 56 (13) | 17 (37) | 30 (53) | 103 (7) | |
| Additional treatment and details of chemotherapy among chemotherapy-treated men, No. (%) | ||||||||
| RPLND | — | — | — | 277 (65) | 40 (87) | 40 (70) | — | .01 |
| Radiotherapy | — | — | — | 41 (10) | 5 (11) | 4 (7) | — | .7 |
| Total No. of chemotherapy cycles, median (range) | — | — | — | 4 (1–9) | 6 (5–23) | 4 (2–14) | — | |
| Total No. of cisplatin-based cycles, median (range) | — | — | — | 4 (1–4) | 6 (5–12) | 4 (2–14) | — | <.001║ |
| Total No. of cisplatin-based dose-intensive cycles, median (range) (percentage of total No. of cisplatin-based cycles, median [range]) | — | — | — | 0 | 0 | 3 (1–6) (67 [14–100]) | — | |
| Median cumulative chemotherapy dose (range) | ||||||||
| Cisplatin, mg | — | — | — | 750 (185–1000) | 1200 (800–2120) | 1120 (370–3095) | — | <.001║ |
| Bleomycin, IU | — | — | — | 300 000 (0–390 000) | 300 000 (0–435 000) | 290 000 (90 000–540 000) | — | .001║ |
| Etoposide, mg | — | — | — | 2195 (0–8550) | 4810 (0–10 580) | 3030 (0–9720) | — | <.001║ |
| Vinblastine, mg | — | — | — | 0 (0–108) | 0 (0–90) | 0 (0–93) | — | <.001║ |
| Smoking status#, No. (%) | .001 | |||||||
| Never daily | 42 (39) | 49 (33) | 178 (31) | 150 (38) | 15 (34) | 28 (55) | 462 (35) | |
| Former daily | 41 (38) | 50 (34) | 178 (31) | 96 (24) | 8 (18) | 5 (10) | 378 (29) | |
| Current daily | 25 (23) | 49 (33) | 213 (38) | 153 (38) | 21 (48) | 18 (35) | 479 (36) | |
| Educational level, No. (%)** | .37 | |||||||
| Primary, middle, or high school | 68 (58) | 100 (65) | 359 (60) | 261 (63) | 32 (70) | 38 (69) | 858 (62) | |
| College or university | 49 (42) | 53 (35) | 244 (40) | 154 (37) | 14 (30) | 17 (31) | 531 (38) | |
| Marital status, No. (%)†† | .02 | |||||||
| Unmarried or living alone | 24 (20) | 23 (15) | 134 (22) | 85 (20) | 16 (35) | 18 (33) | 300 (21) | |
| Married or cohabitating | 95 (80) | 130 (85) | 472 (78) | 334 (80) | 30 (65) | 37 (67) | 1098 (79) | |
— = not applicable; RPLND = retroperitoneal lymph node dissection; RT = radiotherapy.
Some men treated with chemotherapy also received radiotherapy or RPLND.
In the dose-intensive group, 29 patients received one to four cycles and 28 patients received five or more cycles.
Two-sided χ2 test except where indicated.
Two-sided Kruskal–Wallis test.
Royal Marsden Hospital staging system (18) stage IM indicates elevated tumor markers without radiological evidence of metastases.
Data missing for 90 patients (surveillance: 11 patients; RPLND: five patients; radiotherapy: 40 patients; one to four cycles: 26 patients; five or more cycles: two patients; dose intensive: six patients).
Data missing for 20 patients (surveillance: two patients; radiotherapy: six patients; one to four cycles: 10 patients; dose intensive: two patients).
Data missing for 11 patients (radiotherapy: three patients; one to four cycles: six patients; dose intensive: two patients).